ADT 0 3 0 3 B-chronic_disease
, 3 4 3 4 O
it 5 7 5 7 O
may 8 11 8 11 O
only 12 16 12 16 O
be 17 19 17 19 O
given 20 25 20 25 O
for 26 29 26 29 O
a 30 31 30 31 O
maximum 32 39 32 39 O
of 40 42 40 42 O
6 43 44 43 44 B-upper_bound
months 45 51 45 51 I-upper_bound

ECOG 0 4 52 56 B-clinical_variable
Performance 5 16 57 68 I-clinical_variable
Status 17 23 69 75 I-clinical_variable
0 24 25 76 77 B-lower_bound
- 25 26 77 78 O
2 26 27 78 79 B-upper_bound

Excluded 0 8 80 88 O
are 9 12 89 92 O
those 13 18 93 98 O
in 19 21 99 101 O
the 22 25 102 105 O
following 26 35 106 115 O
risk 36 40 116 120 O
groups 41 47 121 127 O
: 47 48 127 128 O
Low 49 52 129 132 O
risk 53 57 133 137 O
; 57 58 137 138 O
High 59 63 139 143 O
risk 64 68 144 148 O
with 69 73 149 153 O
more 74 78 154 158 O
than 79 83 159 163 O
1 84 85 164 165 B-lower_bound
high 86 90 166 170 O
risk 91 95 171 175 O
factor 96 102 176 182 O
; 102 103 182 183 O
Locally 104 111 184 191 O
advanced 112 120 192 200 O
/ 120 121 200 201 O
very 121 125 201 205 O
high 126 130 206 210 O
risk 131 135 211 215 O
= 135 136 215 216 O
T3b 136 139 216 219 B-cancer
- 139 140 219 220 O
T4 140 142 220 222 B-cancer
; 142 143 222 223 O
Metastatic 144 154 224 234 B-cancer
: 154 155 234 235 O
N1 156 158 236 238 O
or 159 161 239 241 O
M1 162 164 242 244 O

HIV+ 0 4 245 249 B-chronic_disease
patients 5 13 250 258 O

High 0 4 259 263 O
Risk 5 9 264 268 O
with 10 14 269 273 O
a 15 16 274 275 O
single 17 23 276 282 O
high 24 28 283 287 O
risk 29 33 288 292 O
feature 34 41 293 300 O
is 42 44 301 303 O
defined 45 52 304 311 O
as 53 55 312 314 O
having 56 62 315 321 O
only 63 67 322 326 O
one 68 71 327 330 O
of 72 74 331 333 O
the 75 78 334 337 O
following 79 88 338 347 O
: 88 89 347 348 O
PSA>20 90 96 349 355 B-clinical_variable
ng 97 99 356 358 I-lower_bound
/ 99 100 358 359 I-lower_bound
ml 100 102 359 361 I-lower_bound
, 102 103 361 362 O
Gleason 104 111 363 370 B-clinical_variable
score 112 117 371 376 I-clinical_variable
8 118 119 377 378 B-lower_bound
- 119 120 378 379 O
10 120 122 379 381 B-upper_bound
, 122 123 381 382 O
or 124 126 383 385 O
T3a 127 130 386 389 O

Known 0 5 390 395 O
sensitivity 6 17 396 407 O
or 18 20 408 410 O
allergic 21 29 411 419 O
reactions 30 39 420 429 O
to 40 42 430 432 O
acyclovir 43 52 433 442 B-allergy_name
or 53 55 443 445 O
valacyclovir 56 68 446 458 B-allergy_name

Liver 0 5 459 464 B-chronic_disease
disease 6 13 465 472 I-chronic_disease
, 13 14 472 473 O
including 15 24 474 483 O
known 25 30 484 489 O
cirrhosis 31 40 490 499 B-chronic_disease
or 41 43 500 502 O
active 44 50 503 509 O
hepatitis 51 60 510 519 B-chronic_disease

Localized 0 9 520 529 B-cancer
prostate 10 18 530 538 I-cancer
cancer 19 25 539 545 I-cancer
meeting 26 33 546 553 O
the 34 37 554 557 O
NCCN 38 42 558 562 O
criteria 43 51 563 571 O
of 52 54 572 574 O
Intermediate 55 67 575 587 O
Risk 68 72 588 592 O
or 73 75 593 595 O
patients 76 84 596 604 O
having 85 91 605 611 O
only 92 96 612 616 O
one 97 100 617 620 O
NCCN 101 105 621 625 O
high 106 110 626 630 O
- 110 111 630 631 O
risk 111 115 631 635 O
feature 116 123 636 643 O

NCCN 0 4 644 648 O
Intermediate 5 17 649 661 O
Risk 18 22 662 666 O
is 23 25 667 669 O
defined 26 33 670 677 O
as 34 36 678 680 O
having 37 43 681 687 O
at 44 46 688 690 O
least 47 52 691 696 O
one 53 56 697 700 B-lower_bound
of 57 59 701 703 O
the 60 63 704 707 O
following 64 73 708 717 O
: 73 74 717 718 O
PSA 75 78 719 722 B-clinical_variable
10 79 81 723 725 B-lower_bound
- 81 82 725 726 O
20 82 84 726 728 B-upper_bound
ng 85 87 729 731 I-upper_bound
/ 87 88 731 732 I-upper_bound
ml 88 90 732 734 I-upper_bound
, 90 91 734 735 O
Gleason 92 99 736 743 B-clinical_variable
score 100 105 744 749 I-clinical_variable
= 106 107 750 751 O
7 107 108 751 752 O
, 108 109 752 753 O
T2b 110 113 754 757 B-lower_bound
- 113 114 757 758 O
T2c 114 117 758 761 B-upper_bound

Patients 0 8 762 770 O
on 9 11 771 773 O
systemic 12 20 774 782 B-treatment
corticosteroids 21 36 783 798 I-treatment
( 37 38 799 800 O
> 38 39 800 801 O
10 39 41 801 803 B-lower_bound
mg 41 43 803 805 I-lower_bound
prednisone 44 54 806 816 I-lower_bound
per 55 58 817 820 I-lower_bound
day 59 62 821 824 I-lower_bound
) 62 63 824 825 O
or 64 66 826 828 O
other 67 72 829 834 O
immunosuppressive 73 90 835 852 B-treatment
drugs 91 96 853 858 I-treatment

Patients 0 8 859 867 O
planning 9 17 868 876 O
to 18 20 877 879 O
receive 21 28 880 887 O
whole 29 34 888 893 B-treatment
pelvic 35 41 894 900 I-treatment
irradiation 42 53 901 912 I-treatment

Patients 0 8 913 921 O
who 9 12 922 925 O
had 13 16 926 929 O
or 17 19 930 932 O
plan 20 24 933 937 O
to 25 27 938 940 O
have 28 32 941 945 O
orchiectomy 33 44 946 957 B-treatment
as 45 47 958 960 O
the 48 51 961 964 O
form 52 56 965 969 O
of 57 59 970 972 O
hormonal 60 68 973 981 O
ablation 69 77 982 990 B-treatment

Planning 0 8 991 999 O
to 9 11 1000 1002 O
undergo 12 19 1003 1010 O
standard 20 28 1011 1019 B-treatment
prostate 29 37 1020 1028 I-treatment
- 37 38 1028 1029 I-treatment
only 38 42 1029 1033 I-treatment
external 43 51 1034 1042 I-treatment
beam 52 56 1043 1047 I-treatment
radiation 57 66 1048 1057 I-treatment
therapy 67 74 1058 1065 I-treatment

Prior 0 5 1066 1071 B-treatment
treatment 6 15 1072 1081 I-treatment
for 16 19 1082 1085 O
prostate 20 28 1086 1094 B-cancer
cancer 29 35 1095 1101 I-cancer
, 35 36 1101 1102 O
except 37 43 1103 1109 O
TURP 44 48 1110 1114 B-treatment
or 49 51 1115 1117 O
ADT 52 55 1118 1121 B-treatment

Regional 0 8 1122 1130 O
lymph 9 14 1131 1136 O
node 15 19 1137 1141 O
involvement 20 31 1142 1153 O
or 32 34 1154 1156 O
distant 35 42 1157 1164 B-cancer
metastases 43 53 1165 1175 I-cancer

